23:55 , Jul 13, 2017 |  BC Week In Review  |  Company News

Almirall lowers guidance

Almirall S.A. (Madrid:ALM) lowered its 2017 top-line and earnings guidance. The dermatology company now expects 2017 revenues and sales to fall in the low double digits compared to 2016, and it guided to EBITDA of...
22:18 , Jul 10, 2017 |  BC Extra  |  Financial News

Almirall sags after lowering guidance

Almirall S.A. (Madrid:ALM) fell €3.21 (25%) to €9.80 on Monday after lowering its 2017 top-line and earnings guidance. The dermatology company now expects 2017 revenues and sales to fall in the low double digits compared...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Clinical News

Acticlate doxycycline hyclate regulatory update

Almirall’s Aqua Pharmaceuticals LLC unit said FDA approved an NDA for Acticlate doxycycline hyclate to treat several infections, including adjunctive treatment of severe acne. The company plans to begin marketing the oral tetracycline antibiotic “in...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Clinical News

Doryx doxycycline hyclate delayed-release tablet regulatory update

FDA approved a 200 mg dose of tetracycline oral antibiotic Doryx doxycycline hyclate delayed-release tablet from Mayne's U.S. marketing partner Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland). Warner Chilcott plans to launch the dose in...
07:00 , May 7, 2012 |  BC Week In Review  |  Company News

Warner Chilcott, Impax, Mylan infectious news

Warner Chilcott said the U.S. District Court for the District of New Jersey ruled in favor of Mylan and Impax in a patent infringement suit brought by Warner Chilcott related to a generic version of...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Clinical News

Doryx doxycycline hyclate delayed-release tablet regulatory update

FDA accepted for filing a Citizen's Petition from Mayne's marketing partner Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) asking the agency not to grant final approval of ANDAs for generic versions of 150 mg Doryx...
08:00 , Feb 17, 2004 |  BC Extra  |  Clinical News

CGPI rosacea Phase III data

CollaGenex (CGPI) said preliminary data from a Phase III trial in 134 patients with rosacea showed that Periostat doxycycline hyclate tablets significantly reduced the number of inflammatory lesions compared to placebo (p=0.009). Clinical disease severity...
07:00 , Aug 19, 2002 |  BC Week In Review  |  Clinical News

Periostat doxycycline: Phase III; marketed to treat periodontal disease

CGPI started a double-blind U.S. Phase III trial of its Periostat in up to 210 patients with rosacea, a chronic inflammatory disease characterized by redness of skin and lesions. CollaGenex Pharmaceuticals Inc. (CGPI), Newtown, Penn....
08:00 , Feb 22, 1999 |  BioCentury  |  Tools & Techniques

Inflection points

As news watchers come to realize, seemingly independent events have a way of piling up on themselves and pushing other topics into the background. With the stars thus aligned, it becomes impossible to ignore the...
07:00 , Sep 14, 1998 |  BC Week In Review  |  Clinical News

Atrix regulatory update

ATRX received received FDA marketing approval for its Atridox doxycycline hyclate 10 percent site-specific antibiotic to treat periodontal disease. The company also received 510(k) clearance from the FDA for its Atrisorb FreeFlow...